Stocktoria

AtriCure, Inc. ATRC

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
7/9
Piotroski F — financial health
3.44
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$534.5M-$11.4M$400.8M$48.3M$491.9M
2024$465.3M-$44.7M$347.5M$745,000$461.0M
2023$399.2M-$30.4M$300.4M-$7.5M$466.2M
2022$330.4M-$46.5M$245.9M-$39.0M$456.8M
2021$274.3M$50.2M$205.9M-$23.5M$483.8M
2020$206.5M-$48.2M$149.3M-$25.1M$412.4M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Prange Karendirector2026-05-20Sell3,000$28.65
Prange Karendirector2026-05-18Grant6,144
Telman Deborah Hdirector2026-05-18Grant6,144
Yuen Maggiedirector2026-05-18Grant6,144
Nachman Shlomodirector2026-05-18Grant6,144
JOHNSON B KRISTINEdirector2026-05-18Grant6,144
GROVES REGINA Edirector2026-05-18Grant6,144
WEHRWEIN SVENdirector2026-05-18Grant6,144

Why these scores methodology →

Piotroski F-score: 7/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 3.44 (safe)

  • Working capital / assets 0.368
  • Retained earnings / assets -0.632
  • EBIT / assets -0.014
  • Equity / liabilities 3.032

Source: SEC EDGAR filings · CIK 0001323885 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.